SG11202110301TA - Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof - Google Patents
Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereofInfo
- Publication number
- SG11202110301TA SG11202110301TA SG11202110301TA SG11202110301TA SG11202110301TA SG 11202110301T A SG11202110301T A SG 11202110301TA SG 11202110301T A SG11202110301T A SG 11202110301TA SG 11202110301T A SG11202110301T A SG 11202110301TA SG 11202110301T A SG11202110301T A SG 11202110301TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- bioconjugates
- coli
- production
- antigen polysaccharides
- Prior art date
Links
- 241000588724 Escherichia coli Species 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 150000004676 glycans Chemical class 0.000 title 1
- 229920001282 polysaccharide Polymers 0.000 title 1
- 239000005017 polysaccharide Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819746P | 2019-03-18 | 2019-03-18 | |
| PCT/US2020/023404 WO2020191082A1 (en) | 2019-03-18 | 2020-03-18 | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110301TA true SG11202110301TA (en) | 2021-10-28 |
Family
ID=70285927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110301TA SG11202110301TA (en) | 2019-03-18 | 2020-03-18 | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11446370B2 (en) |
| EP (1) | EP3941516A1 (en) |
| JP (1) | JP7370391B2 (en) |
| KR (1) | KR102532707B1 (en) |
| CN (1) | CN113924112A (en) |
| AR (1) | AR118388A1 (en) |
| AU (1) | AU2020240072A1 (en) |
| BR (1) | BR112021018236A2 (en) |
| CA (1) | CA3134216A1 (en) |
| CL (1) | CL2021002426A1 (en) |
| CO (1) | CO2021013823A2 (en) |
| CR (1) | CR20210522A (en) |
| EA (1) | EA202192390A1 (en) |
| IL (1) | IL286394A (en) |
| JO (1) | JOP20210256A1 (en) |
| MA (1) | MA55364A (en) |
| MX (1) | MX2021011445A (en) |
| PE (1) | PE20212265A1 (en) |
| SA (1) | SA521430310B1 (en) |
| SG (1) | SG11202110301TA (en) |
| TW (1) | TWI751513B (en) |
| UY (1) | UY38616A (en) |
| WO (1) | WO2020191082A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2669420T3 (en) | 2013-01-17 | 2018-05-25 | Arsanis Biosciences Gmbh | E.coli MDR specific antibody |
| MX2016011055A (en) | 2014-02-24 | 2017-10-24 | Glycovaxyn Ag | Novel polysaccharide and uses thereof. |
| AR109621A1 (en) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | FORMULATIONS OF VACCINES AGAINST GLUCOCONJUGADOS OF EXPEC |
| WO2020191082A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
| AR118389A1 (en) | 2019-03-18 | 2021-09-29 | Janssen Pharmaceuticals Inc | PRODUCTION METHODS OF BIOCONJUGATES OF POLYSACCHARIDES OF E. COLI O-ANTIGEN, THEIR COMPOSITIONS AND METHODS OF USE |
| EP4213870A1 (en) * | 2020-09-17 | 2023-07-26 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
| WO2022113048A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceuticals, Inc. | Analytical method for glycoconjugates using a capillary-based immunoassay system |
| TW202304504A (en) | 2021-04-01 | 2023-02-01 | 美商詹森藥物公司 | Production of e. coli o18 bioconjugates |
| KR20240005684A (en) | 2021-04-08 | 2024-01-12 | 얀센 파마슈티칼즈, 인코포레이티드 | Bioconjugate production method |
| CN116003531B (en) * | 2022-12-28 | 2023-09-05 | 山东省农业科学院畜牧兽医研究所 | Application of phage receptor binding protein PO86 in genotyping identification of E.coli O antigen |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422653D0 (en) | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
| DK0671948T3 (en) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccine containing adjuvants |
| AUPM399594A0 (en) | 1994-02-21 | 1994-03-17 | Csl Limited | Antigenic preparation for treatment or prevention of helicobacter infection |
| US6491919B2 (en) | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
| CN1326564C (en) | 1997-04-01 | 2007-07-18 | 科里克萨有限公司 | Aqueous immunologic adjuvant compositions of monophosphoryl lipid A |
| US6858211B1 (en) | 1998-07-20 | 2005-02-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccines against Escherichia coli O157 infection |
| PT1126876E (en) | 1998-10-16 | 2007-04-30 | Glaxosmithkline Biolog Sa | Adjuvant systems and vaccines |
| DE60134499D1 (en) | 2000-04-13 | 2008-07-31 | Corixa Corp | IMMUNOSTIMULATING COMBINATIONS CONTAINING AMINO ALKYL GLUCOSAMINE IDEPHOSPHATE AND QS-21 |
| AU2001253568A1 (en) | 2000-04-18 | 2001-10-30 | Dan C. Deborde | Lipopolysaccharide-conjugate vaccine for sepsis treatment |
| RU2189253C1 (en) | 2001-04-09 | 2002-09-20 | Государственный научный центр прикладной микробиологии | Diagnosticum for identification of escherichia coli 0157:h7 and method of its preparing |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| US6676958B2 (en) | 2001-06-19 | 2004-01-13 | Advanced Bioadjuvants, Llc | Adjuvant composition for mucosal and injection delivered vaccines |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| KR20090110951A (en) | 2002-03-07 | 2009-10-23 | 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 | System and method for the production of recombinant glycosylated protein in a prokaryotic host |
| AU2003901008A0 (en) | 2003-03-04 | 2003-03-20 | Anadis Ltd | Composition for the treatment and prevention of bacterial infections |
| CA2561577A1 (en) | 2004-03-30 | 2005-10-13 | Nsgene A/S | Therapeutic use of a growth factor, nsg33 |
| EP2853600B1 (en) | 2005-05-11 | 2018-09-19 | ETH Zürich | Recombinant N-glycosylated proteins from procaryotic cells |
| TWI457133B (en) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | Novel composition |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| ATE539079T1 (en) | 2006-03-23 | 2012-01-15 | Novartis Ag | IMIDAZOCHINOXALINE COMPOUNDS AS IMMUNE MODULATORS |
| JP4791866B2 (en) | 2006-03-24 | 2011-10-12 | 国立大学法人秋田大学 | Solid phase used for discrimination of diarrheagenic Escherichia coli infection |
| US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| JP5647899B2 (en) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | Glycoconjugation of polypeptides using oligosaccharyltransferase |
| WO2009104074A2 (en) | 2008-02-20 | 2009-08-27 | Glycovaxyn Ag | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
| KR101785120B1 (en) | 2009-04-27 | 2017-10-12 | 이뮤론 리미티드 | Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder |
| TWI494125B (en) | 2009-06-05 | 2015-08-01 | Infectious Disease Res Inst | Synthetic glucopyranosyl lipid adjuvants |
| HUE038456T2 (en) | 2009-11-19 | 2018-10-29 | Glaxosmithkline Biologicals Sa | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| CN105734678B (en) | 2010-07-16 | 2019-11-05 | 阿迪马布有限责任公司 | Synthetic polyribonucleotides library |
| AR084158A1 (en) | 2010-12-10 | 2013-04-24 | Merck Sharp & Dohme | FORMULATIONS THAT MITIGATE THE AGGREGATION INDUCED BY AGMATION OF IMMUNOGENIC COMPOSITIONS |
| JP2014526449A (en) | 2011-09-06 | 2014-10-06 | グリコヴァキシン アーゲー | Bioconjugate vaccine produced in prokaryotic cells |
| US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
| JP2015529214A (en) | 2012-09-10 | 2015-10-05 | グリコヴァキシン アーゲー | Bioconjugates containing modified antigens and uses thereof |
| EA201590488A1 (en) | 2012-10-12 | 2015-09-30 | Гликоваксин Аг | METHODS OF MODIFICATION OF CELL-OWNERS |
| ES2750525T3 (en) | 2012-12-27 | 2020-03-26 | Glaxosmithkline Biologicals Sa | Procedures and compositions related to CRM197 |
| ES2669420T3 (en) | 2013-01-17 | 2018-05-25 | Arsanis Biosciences Gmbh | E.coli MDR specific antibody |
| PL2996473T3 (en) | 2013-05-18 | 2020-06-01 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| EP3055416B1 (en) | 2013-10-11 | 2020-01-22 | GlaxoSmithKline Biologicals S.A. | Methods of host cell modification |
| AU2014359277B2 (en) | 2013-12-04 | 2017-10-26 | Glaxosmithkline Biologicals S.A. | Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli |
| MX2016008794A (en) | 2014-02-06 | 2016-10-13 | Arsanis Biosciences Gmbh | E. coli specific antibody sequences. |
| MX2016011055A (en) | 2014-02-24 | 2017-10-24 | Glycovaxyn Ag | Novel polysaccharide and uses thereof. |
| ES2939470T3 (en) | 2014-04-17 | 2023-04-24 | Glaxosmithkline Biologicals Sa | Modified host cells and uses thereof |
| CN105695497B (en) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | A kind of preparation method and applications of the recombination fusion protein of bacterial polysaccharides modification |
| WO2016107819A1 (en) | 2014-12-30 | 2016-07-07 | Glycovaxyn Ag | Compositions and methods for protein glycosylation |
| TWI715617B (en) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| AR109621A1 (en) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | FORMULATIONS OF VACCINES AGAINST GLUCOCONJUGADOS OF EXPEC |
| GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2020191082A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof |
| AR118389A1 (en) | 2019-03-18 | 2021-09-29 | Janssen Pharmaceuticals Inc | PRODUCTION METHODS OF BIOCONJUGATES OF POLYSACCHARIDES OF E. COLI O-ANTIGEN, THEIR COMPOSITIONS AND METHODS OF USE |
| FR3098334B1 (en) | 2019-07-05 | 2021-07-23 | Airbus Operations Sas | Method and system for monitoring a state of consciousness of an operator in a cockpit of an aircraft |
| EP4213870A1 (en) | 2020-09-17 | 2023-07-26 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
-
2020
- 2020-03-18 WO PCT/US2020/023404 patent/WO2020191082A1/en active Application Filing
- 2020-03-18 CA CA3134216A patent/CA3134216A1/en active Pending
- 2020-03-18 TW TW109109075A patent/TWI751513B/en active
- 2020-03-18 CN CN202080037067.6A patent/CN113924112A/en active Pending
- 2020-03-18 JP JP2021556247A patent/JP7370391B2/en active Active
- 2020-03-18 MA MA055364A patent/MA55364A/en unknown
- 2020-03-18 EA EA202192390A patent/EA202192390A1/en unknown
- 2020-03-18 SG SG11202110301TA patent/SG11202110301TA/en unknown
- 2020-03-18 EP EP20718989.5A patent/EP3941516A1/en active Pending
- 2020-03-18 PE PE2021001476A patent/PE20212265A1/en unknown
- 2020-03-18 MX MX2021011445A patent/MX2021011445A/en unknown
- 2020-03-18 AU AU2020240072A patent/AU2020240072A1/en active Pending
- 2020-03-18 UY UY0001038616A patent/UY38616A/en unknown
- 2020-03-18 JO JOP/2021/0256A patent/JOP20210256A1/en unknown
- 2020-03-18 BR BR112021018236A patent/BR112021018236A2/en unknown
- 2020-03-18 CR CR20210522A patent/CR20210522A/en unknown
- 2020-03-18 US US16/822,340 patent/US11446370B2/en active Active
- 2020-03-18 KR KR1020217033424A patent/KR102532707B1/en active IP Right Grant
- 2020-03-18 AR ARP200100746A patent/AR118388A1/en unknown
-
2021
- 2021-09-14 IL IL286394A patent/IL286394A/en unknown
- 2021-09-16 CL CL2021002426A patent/CL2021002426A1/en unknown
- 2021-09-16 SA SA521430310A patent/SA521430310B1/en unknown
- 2021-10-14 CO CONC2021/0013823A patent/CO2021013823A2/en unknown
-
2022
- 2022-07-28 US US17/815,705 patent/US11931405B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200316184A1 (en) | 2020-10-08 |
| PE20212265A1 (en) | 2021-11-30 |
| TWI751513B (en) | 2022-01-01 |
| IL286394A (en) | 2021-10-31 |
| AR118388A1 (en) | 2021-09-29 |
| MX2021011445A (en) | 2021-10-13 |
| US20230118878A1 (en) | 2023-04-20 |
| TW202102255A (en) | 2021-01-16 |
| SA521430310B1 (en) | 2023-12-13 |
| KR20210141586A (en) | 2021-11-23 |
| US11931405B2 (en) | 2024-03-19 |
| JP2022533883A (en) | 2022-07-27 |
| BR112021018236A2 (en) | 2021-11-23 |
| CR20210522A (en) | 2021-12-17 |
| CA3134216A1 (en) | 2020-09-24 |
| KR102532707B1 (en) | 2023-05-12 |
| WO2020191082A1 (en) | 2020-09-24 |
| CL2021002426A1 (en) | 2022-04-29 |
| WO2020191082A9 (en) | 2020-11-05 |
| CN113924112A (en) | 2022-01-11 |
| US11446370B2 (en) | 2022-09-20 |
| MA55364A (en) | 2022-01-26 |
| UY38616A (en) | 2020-09-30 |
| CO2021013823A2 (en) | 2022-03-29 |
| AU2020240072A1 (en) | 2021-10-28 |
| EA202192390A1 (en) | 2021-12-03 |
| JOP20210256A1 (en) | 2023-01-30 |
| JP7370391B2 (en) | 2023-10-27 |
| EP3941516A1 (en) | 2022-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286394A (en) | Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof | |
| IL286467A (en) | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof | |
| EP3668497A4 (en) | Methods and compositions for the treatment of diseases associated with cancer, inflammation, or immune response | |
| MX2019012534A (en) | Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent. | |
| IL272919A (en) | Metabolic engineering of e. coli for the biosynthesis of cannabinoid products | |
| EP3733809A4 (en) | Water repellent agent composition, and production method of water repellent fiber product | |
| EP3658025A4 (en) | Catheter assemblies, oxygen-sensing assemblies, and related methods | |
| EP3684434A4 (en) | Tissue construct, methods of producing and using the same | |
| EP4293033A3 (en) | Alpha (1,2) fucosyltransferase syngenes for use in the production of fucosylated oligosaccharides | |
| WO2015164392A8 (en) | Novel anti-rnf43 antibodies and methods of use | |
| WO2019053661A3 (en) | Galnac derivatives | |
| ZA202008011B (en) | Polyether derivatives, uses, and methods of making the same | |
| MX2019008546A (en) | Therapeutic uses of an insect powder. | |
| EP3518985A4 (en) | Aavrh.10 variants with host antibody escape capabilities and altered tissue targeting properties | |
| EP3720842A4 (en) | Acyl hydrazone linkers, methods and uses thereof | |
| MX2018002416A (en) | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the prodcution and use thereof. | |
| WO2017096303A3 (en) | Cerdulatinib for treating hematological cancers | |
| EP3669041A4 (en) | Doors comprising glazed unit, and method of making the same | |
| MX2019013250A (en) | 2,3,7-trimethyloct-6-enyl acetate and 3,7-dimethyl-2-methylene-oc t-6-enyl acetate and derivatives thereof and their use as aroma chemicals. | |
| EP3572392A4 (en) | Method for producing fluorenylidene diallylphenols, and fluorenylidene diallylphenols | |
| EP3622830A4 (en) | Grooved noodle, grooved noodle production method, and grooved noodle cooking method | |
| EP3612549A4 (en) | Lantibiotics, lantibiotic-producing bacteria, compositions and methods of production and use thereof | |
| PH12019502315A1 (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
| SG11202104018TA (en) | An implantable construct, methods of manufacturing, and uses thereof | |
| EP3700569A4 (en) | H1.0k180me2 antibodies, methods of making and uses thereof |